Advisory Board

Dr. Jeffrey Hyams, Director, Gastroenterology Department, Connecticut Children’s Medical Center

Dr. Hyams is a consultant to Immune Therapeutics on Crohn’s disease. He is head of the division of digestive diseases, hepatology, and nutrition at Connecticut Children’s Medical Center and professor of pediatrics at the University of Connecticut. Dr. Hyams has been given the Scientific Achievement in IBD Clinical Research Award by the Crohn’s and Colitis Foundation of America (CCFA). In his research, Dr. Hyams focuses on two areas. The first is inflammatory bowel disease in children, where he has been involved in developing strategies for assessing disease activities to facilitate clinical trials, investigating mechanisms of growth failure in the children, establishing a North American registry for newly diagnosed patients, and participating in conducting clinical trials. The second area of research focus for Dr. Hyams is functional gastrointestinal disorders, particularly irritable bowel syndrome and nonulcer dyspepsia. He is a member of the ROME committee, an international group establishing diagnosis guidelines for the disorders. Dr. Hyams also works with the American Academy of Pediatrics to establish practice guidelines for children with chronic abdominal pain.

Dr. Ian S. Zagon

Dr. Zagon is professor of neuroscience and anatomy at The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania. He holds membership in the Specialized Cancer Research Center, Intercollege Graduate Program in Genetics, Cell and Molecular Biology Graduate Program Neuroscience Graduate Program, M.D./Ph.D. Program, and the Integrative Biosciences Graduate Program-Molecular Medicine, Neuroscience, and Cell and Developmental Biology. Dr. Zagon was born in New York City. In 1972, he accepted a position as assistant professor in the department of anatomy, University of Miami Medical School. He relocated to the Department of Anatomy (now the Department of Neuroscience and Anatomy) at The Pennsylvania State University College of Medicine, in Hershey in 1974. His early interests focused on the etiology and pathogenesis of brain tumors. However, another research project that served as the root of investigations for over a quarter of a century was initiated at this time: opioid peptides, opioid receptors, and growth, and a team effort with Dr. Patricia J. McLaughlin, Associate Professor of Neuroscience and Anatomy, was formed. These early studies examined the repercussions of maternal opioid abuse (methadone, morphine, and heroin) on the outcome of offspring, particularly those concerned with the nervous system. These researchers learned that such drugs of abuse have a marked negative impact on brain development, and that these alterations influence the infant, adolescent, and adult anatomy of the nervous system as well as cognition and behavior. Dr. Zagon has been a co-organizer of national and international meetings on developmental biology and cancer, and he serves (and has served) on the editorial board of five journals. Dr. Zagon has authored more than 240 publications, as well as 200 presentations and invited talks, and has published three books. He has received numerous grants from a variety of agencies, including the National Institutes of Health, the American Cancer Society, and the American Heart Association, and has been awarded six patents. For the past 19 years, Dr. Zagon has received a Distinguished Teaching Award by the medical students.

Terry Grossman, M.D.

Dr. Grossman is the founder and medical director of the Grossman Wellness Center in Denver, Colorado. His longevity medical practice attracts patients, including many VIPs (such as coauthor Ray Kurzweil) from around the country and the world. He graduated from Brandeis University in 1968 and the University of Florida School of Medicine in 1979. He spent 15 years (from 1980-1995) working as a community family doctor in the Colorado mountains. Dr. Grossman undertook the study of nutritional and anti-aging medicine in 1994 and in 1995 opened the Grossman Wellness Center in Denver, which quickly grew into one of the largest complementary medical centers in the country. He is a member and board certified by the American Academy of Anti-Aging Medicine as well as the American Holistic Medical Association. His special field of interest is nutritional medicine (the treatment of illness with nutrients such as vitamins, minerals, anti-oxidants and natural hormones) and anti-aging medicine. Dr. Grossman is a widely sought lecturer on longevity medicine throughout the U.S. and has presented keynote addresses at anti-aging seminars in Japan, South Korea, South Africa, and elsewhere. He is the author of the Baby Boomers’ Guide to Living Forever (2000), and coauthor with Ray Kurzweil of Fantastic Voyage (2004), and TRANSCEND: Nine Steps to Living Well Forever (2009).

Dr. Patricia J. McLaughlin

Dr. McLaughlin received post-baccalaureate training at Penn State University and began working in the laboratory with Dr. Zagon (see above) in the mid-1970s. In collaboration with Dr. Zagon, Dr. McLaughlin first discovered the effects of LDN in 1979, and published a seminal paper in Science in 1983, describing the potential benefits of LDN. Dr. McLaughlin is currently a tenured professor, director of the Anatomy Graduate Program at the College of Medicine, and heads laboratory research on the use of OGF and LDN in cancer, multiple sclerosis, and diabetic-associated wound healing.

Dr. Jill Smith

Dr. Jill Smith is a gastroenterologist in Hershey, Pennsylvania and is affiliated with Penn State Milton S. Hershey Medical Center. She received a medical degree from University of Florida College of Medicine and has been in practice for 34 years. She is one of 15 doctors at Penn State Milton S. Hershey Medical Center who specialize in Gastroenterology. Research interests are directed towards understanding the regulation of growth of gastrointestinal malignancies. Gastrointestinal peptides that regulate growth and development of the normal GI tract appear to also regulate growth of various GI cancers. Dr. Smith has shown that selective receptor antagonists of gastrin and cholecystokinin inhibit growth of human colon and pancreatic cancer. The intracellular and molecular mechanisms of growth of several GI cancers are being investigated. The research lab has been studying the molecular aspects of some unique receptors on pancreatic cancer cells and actively performs procedures such as PCR, gel electrophoresis, cloning, and sequencing. Dr. Smith has shown that endogenous [Met5]-enkephalin, opioid growth factor inhibits growth of pancreatic and colon cancer. The mechanism involved in the growth inhibition by OGF is being sought, and appears to involve a defect in the autocrine loop. Two NIH grants support this research including a Phase I trial in humans, with several clinical trials underway. Dr. Smith is the principal investigator on three research grants from the National Institute of Health (NIH) and has support from industry for other projects. As a clinician scientist, Dr. Smith is also actively involved in clinical research. She has discovered a new antiviral therapy, amantadine, for hepatitis C that improved 70% of patients who had previously failed Interferon therapy, with further clinical trials underway.